8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $376M | -$16M | 90.2% | -3.3% | -$6M | $109M | $43M |
| 2024 | $197M | -$140M | 90.3% | -65.3% | -$112M | $107M | $71M |
| 2023 | $60M | -$262M | 91.6% | -404.5% | -$247M | $202M | $88M |
| 2022 | $4M | -$311M | 79.5% | -8183.0% | -$258M | $198M | $54M |
| 2021 | — | -$206M | — | — | -$176M | $72M | $96M |
| 2020 | — | -$136M | — | — | -$113M | $0 | $65M |
| 2019 | — | -$42M | — | — | -$43M | — | $63M |
| 2018 | — | -$19M | — | — | -$14M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $105M | -$11M | 90.7% | -8.6% | $2M | $109M | $35M |
| Dec '25 | $130M | $17M | 91.0% | 14.2% | $26M | $109M | $43M |
| Sep '25 | $99M | $7M | 91.2% | 8.6% | -$2M | $108M | $47M |
| Jun '25 | $82M | -$16M | 90.8% | -17.9% | $246000 | $108M | $73M |
| Mar '25 | $66M | -$25M | 86.6% | -37.3% | -$31M | $108M | $53M |
| Dec '24 | $71M | -$11M | 90.3% | -10.7% | -$748000 | $107M | $71M |
| Sep '24 | $45M | -$42M | 87.7% | -87.3% | -$35M | $205M | $135M |
| Jun '24 | $31M | -$52M | 88.8% | -162.3% | -$45M | $204M | $84M |
| Mar '24 | $50M | -$35M | 93.4% | -63.8% | -$32M | $203M | $190M |
| Dec '23 | $14M | -$66M | 83.4% | -452.2% | -$56M | $202M | $88M |
| Sep '23 | $38M | -$45M | 96.9% | -96.8% | -$44M | $201M | $107M |
| Jun '23 | $5M | -$71M | 85.0% | -1286.4% | -$67M | $200M | $105M |
| Mar '23 | $3M | -$80M | 71.8% | -2742.4% | -$80M | $199M | $81M |
| Dec '22 | — | -$72M | — | — | -$71M | $198M | $54M |
| Sep '22 | — | -$108M | — | — | -$68M | $197M | $82M |
| Jun '22 | $0 | -$67M | — | — | -$62M | $73M | $62M |
| Mar '22 | — | -$64M | — | — | -$57M | $73M | $70M |
| Dec '21 | — | -$71M | — | — | -$52M | $72M | $96M |
| Sep '21 | — | -$57M | — | — | -$41M | — | $52M |
| Jun '21 | — | -$42M | — | — | -$36M | — | $89M |
How the market has priced ARQT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Arcutis Biotherapeutics, Inc.'s revenue has grown 367.3% per year. These are computed facts, not advice.
As of FY2025, Arcutis Biotherapeutics, Inc. reported $109M of total debt against $43M of cash; operating income covered interest expense -1.0×.
In FY2025, gross margin was 90.2%, operating margin -3.3%, and net margin -4.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.